U.S. stock market midday update: Decoy Therapeutics up 19.06%, collaboration with the Gates Foundation boosts antiviral drug development!

U.S. Stock Market Midday Update Decoy Therapeutics rose 19.06%. Based on recent key news: On January 13, Decoy Therapeutics reached an agreement with the Gates Foundation to develop a platform for manufacturing antiviral drugs. This platform aims to make antiviral drugs widely available in low- and middle-income countries, driving the stock price up by 6.99%. Source: Reuters On January 13, the company announced plans to validate its IMP3ACT technology platform and submit an IND application for its main antiviral candidate, enhancing market confidence. Source: Reuters On January 13, Decoy Therapeutics received funding support from the Gates Foundation to expand the global accessibility of its antiviral drugs, further driving the stock price up. Source: Reuters The global pandemic has recurred, increasing the demand for antivirals. Stocks with High Trading Volume in the Industry AbbVie fell 2.26%, with increased trading volume. Based on recent key news: On January 13, AbbVie reached an agreement with the U.S. government to invest $100 billion in U.S. R&D and manufacturing over the next decade in exchange for tariff exemption eligibility. This move aims to improve drug accessibility and lower prices, leading to stock price fluctuations. Source: Zhitong Finance On January 12, AbbVie signed a licensing agreement with Rongchang Biologics, obtaining development rights for RC148 outside Greater China. The total value of the agreement could reach up to $4.95 billion, driving up Rongchang Biologics' stock price. Source: Jinshi Data On January 13, drug pricing policy became a focal point of discussion at the JP Morgan Healthcare Conference, which may affect companies like AbbVie. Source: Zhitong Finance Drug pricing policy impacts market sentiment. Abivax SA fell 4.54%. Based on recent key news: On January 12, French media reported that Eli Lilly plans to acquire Abivax for €15 billion, causing Abivax's stock price to rise over 20% in early trading. This news sparked strong market interest in Abivax, driving stock price fluctuations. On January 12, the French Ministry of Finance stated that it had not yet received any investment approval requests regarding Abivax and had not been in contact with Eli Lilly. This news raised doubts about the actual progress of the acquisition, affecting stock price trends. On January 12, analysts pointed out that Abivax's obefazimod drug performed well in clinical trials, making it a target for acquisition. The potential market value of this drug increased investor interest in Abivax, further driving stock price fluctuations. The biotechnology industry is active in mergers and acquisitions, intensifying market volatility. Regeneron Pharmaceuticals fell 0.81%. Based on recent news, On January 15, analyst Jefferies maintained a buy rating on Regeneron Pharmaceuticals and raised the target price to $885. This move enhanced market confidence in the company, although the stock price declined, trading volume significantly increased On January 14, Regeneron Pharmaceuticals discussed its FDA response regarding its gene therapy for hearing loss and plans to launch a weight loss drug at the JP Morgan Healthcare Conference. This news attracted market attention, leading to stock price fluctuations. On January 15, the global net sales of Dupixent, a blockbuster drug co-marketed by Regeneron Pharmaceuticals and Sanofi, exceeded $19 billion in the fourth quarter. Although the market is confident about the drug's future performance, it is expected to lose market exclusivity by 2031, which may affect long-term revenue expectations. The healthcare sector has performed strongly recently, with significant capital inflows. Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen fell 1.03%, with increased trading volume. Based on recent key news: On January 14, Goldman Sachs pointed out that Amgen's next-generation weight loss drug MariTide has significant catalytic potential, with an expected 30% upside in stock price. Goldman Sachs believes that the rising global obesity rate will drive demand for weight loss drugs, and Amgen's valuation is below the industry average, with a target price of $400. On January 13, Amgen announced that its experimental obesity drug MariTide showed significant reductions in blood sugar and weight in a 24-week study in patients with type 2 diabetes. Most participants maintained weight loss in a 52-week extension study, and the drug was well tolerated. On January 15, Amgen discussed the research results of MariTide at the J.P. Morgan Healthcare Conference, showing positive cardiac metabolic parameter results, further attracting market attention to its stock performance. The biotechnology sector's valuation is below the market average